[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503082":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bupivacaine methylene blue group","EXPERIMENTAL","Patients in this group will receive the following regimen through the perineural catheter:\n\nBolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml\u002Fhour for 72 hours postoperatively",[13],"Drug: Bupivacaine methylene blue",{"label":15,"type":16,"description":17,"interventionNames":18},"Bupivacaine saline group","ACTIVE_COMPARATOR","Patients in this group will receive the following regimen through the perineural catheter:\n\nBolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml\u002Fhour for 72 hours postoperatively",[19],"Drug: bupivacaine saline",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Bupivacaine methylene blue",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"bupivacaine saline",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Osama M Rehab, MD","CONTACT","00201095210806","osamarehab@med.tanta.edu.eg",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Tanta","Gharbia Governorate","31527","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.00192,30.78847,{"lat":47,"lon":46},[50,51],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Doha M Bakr, MD","SUB_INVESTIGATOR",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Osama Rehab","lecturer of anesthesiology, surgical intensive care and pain medicine","100503082","perineural-methylene-blue-infusion-in-lower-limb-amputation-surgery-100503082",false,"NCT05830630","Perineural Methylene Blue Infusion in Lower Limb Amputation Surgery","The Preventive Value of Continuous Perineural Methylene Blue Infusion in Patients Undergoing Lower Limb Amputation Surgery","Inclusion Criteria:\n\n* Patients of both genders, suffering from vascular insufficiency of one or both lower limbs and scheduled for above or below knee amputation under general anesthesia.\n\nExclusion Criteria:\n\n* Patients with a history of allergy to local anesthetics.\n* Patients with allergy to methylene blue.\n* Anticoagulant use or coagulopathy.",true,"ALL","18 Years",{"count":69,"type":70},72,"ESTIMATED","INTERVENTIONAL",[73],"NA","This prospective randomized controlled study will be conducted to evaluate the analgesic effect of continuous perineural infusion of methylene blue with bupivacaine on acute postoperative pain and to evaluate its preventive role against chronic phantom pain in patients undergoing lower limb amputation surgery",[76,77,78],"Perineural","Methylene Blue","Lower Limb Amputation",[76,80,81],"Methylene blue","Lower limb amputation","2025-07-04",{"date":84,"type":85},"2025-07-09","ACTUAL",{"date":87,"type":85},"2023-05-01",{"date":89,"type":70},"2027-05-01",{"name":5,"class":6},1]